NCT00204308View on ClinicalTrials.gov

Maternal TDF and FTC to Reduce NNRTI Resistance Mutations After Intrapartum NVP

PHASE2CompletedINTERVENTIONAL
Enrollment

400

Participants

Timeline

Start Date

March 31, 2005

Primary Completion Date

May 31, 2007

Study Completion Date

May 31, 2007

Conditions
HIVPregnancy
Interventions
DRUG

Combination tenofovir-emtricitabine

Tenofovir disoproxil 300 mg / emtricitabine 200 mg taken as a single dose during labor

Trial Locations (2)

Unknown

Kalingalinga Health Centre, Lusaka

Kanyama Health Centre, Lusaka

All Listed Sponsors
collaborator

Elizabeth Glaser Pediatric AIDS Foundation

OTHER

lead

University of North Carolina, Chapel Hill

OTHER

NCT00204308 - Maternal TDF and FTC to Reduce NNRTI Resistance Mutations After Intrapartum NVP | Biotech Hunter | Biotech Hunter